A Randomised, Double-Blind, Placebo-Controlled, Multi-National, Multi-Centre, Phase III Paediatric Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen-Based Tablets Once Daily to Children Suffering From Grass Pollen Rhinoconjunctivitis.

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, Multi-National, Multi-Centre, Phase III Paediatric Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen-Based Tablets Once Daily to Children Suffering From Grass Pollen Rhinoconjunctivitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
  • Focus Therapeutic Use
  • Sponsors Stallergenes Greer plc; Stallergenes SA
  • Most Recent Events

    • 07 Mar 2016 Pooled analysis of 4 trials (n=891), including this study and 3 other studies [see CTP 700020436, 700039691, 700040181] was presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 04 Jul 2012 Planned number of patients changed from 280 to 350 as reported by European Clinical Trials Database.
    • 17 Mar 2009 Status changed from recruiting to completed, based on reporting of results at AAAAI 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top